| References
|  |
|
| 207 | Ashton AK, Ahrens K, Gupta S, Masand PS. Antidepressant-induced sexual dysfunction and Ginkgo biloba. Am J Psychiatry 2000;157:836-7. |
| 542 | Gordon JB. SSRIs and St. John's Wort: possible toxicity? Am Fam Physician 1998;57:950, 953. |
| 763 | Muller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998;31:16-21. |
| 1292 | Yue QY, Bergquist C, Gerden B. Safety of St. John's wort (Hypericum perforatum). Lancet 2000;355:576-7. |
| 1313 | FDA. Center for Food Safety and Applied Nutrition. Letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart disease. Available at: http://vm.cfsan.fda.gov/~dms/ds-ltr11.html. |
| 1340 | Durr D, Stieger B, Kullak-Ublick GA, et al. St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598-604. |
| 2026 | Levine J, Barak Y, Kofman O, Belmaker RH. Follow-up and relapse analysis of an inositol study of depression. Isr J Psychiatry Relat Sci 1995;32:14-21. |
| 2084 | Zhao G. [Inherited metabolic aberration of phenylalanine in the family members of patients with essential hypertension and stroke]. [Article in Chinese]. Chung Hua I Hsueh Tsa Chih (Taipei) 1991;71:28, 388-90. |
| 2185 | Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995;152:792-4. |
| 2457 | Mosnik DM, Spring B, Rogers K, Baruah S. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients. Neuropsychopharmacology 1997;16:136-46. |
| 2458 | Gardos G, Cole JO, Matthews JD, et al. The acute effects of a loading dose of phenylalanine in unipolar depressed patients with and without tardive dyskinesia. Neuropsychopharmacology 1992;6:241-7. |
| 2468 | Beckmann H, Athen D, Olteanu M, Zimmer R. DL-phenylalanine versus imipramine: a double-blind controlled study. Arch Psychiatr Nervenkr 1979;227:49-58. |
| 2469 | Birkmayer W, Riederer P, Linauer W, Knoll J. L-deprenyl plus L-phenylalanine in the treatment of depression. J Neural Transm 1984;59:81-7. |
| 3091 | Vrecko K, Storga D, Birkmayer JG, et al. NADH stimulates endogenous dopamine biosynthesis by enhancing the recycling of tetrahydrobiopterin in rat phaeochromocytoma cells. Biochim Biophys Acta 1997;1361:59-65. |
| 3270 | Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandosterone. Am J Psychiatry 1999;156:646-9. |
| 3291 | Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984;310:483-8. |
| 3294 | Eriksson T, Granerus AK, Linde A, et al. "On-off" phenomenon in Parkinson's disease: relationship between dopa and other large neutral amino acids in plasma. Neurology 1988;38:1245-8. |
| 3521 | Iruela LM, Minguez L, Merino J, Monedero G. Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry 1993;150:522. |
| 3548 | Kim HL, Streltzer J, Goebert D. St. John's wort for depression: A meta analysis of well-defined clinical trials. J Nerv Ment Dis 1999;187:532-9. |
| 3549 | Linde K, Ramirez G, Mulrow CD, et al. St. John's wort for depression: an overview and meta-analysis of randomized clinical trials. BMJ 1996;313:253-8. |
| 3550 | Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung 1999;49:289-96. |
| 3551 | Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomized mulicentre study of treatment for eight weeks. BMJ 1999;319:1534-9. |
| 3556 | Nebel A, Schneider BJ, Baker RA, et al. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 1999;33:502. |
| 3599 | Markowitz JS, DeVane CL, Boulton DW, et al. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000;66:PL 133-9. |
| 3603 | Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990;16:101-6. |
| 3604 | Tempesta E, Casella L, Pirrongelli C, et al. L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res 1987;13:417-23. |
| 3657 | Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Dis 2000;60:121-31. |
| 3966 | Balon R. Ginkgo biloba for antidepressant-induced sexual dysfunction? J Sex Marital Ther 1999;25:1-2. |
| 4233 | Wolkowitz OM, Reus VI, Manfredi F, et al. Dehydroepiandrosterone (DHEA) treatment of depression. [Abstract] Biol Psychiatry 1997;41:311-8. |
| 4251 | Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. [Abstract] Clin Endocrinol (Oxf)1998;49:421-32. |
| 4521 | Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 2001;68:1593-605. |
| 4835 | Wang Z, Gorski JC, Hamman MA, et al. The effects of St. John's wort (Hyericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-26. |
| 4897 | Schrader E. Equivalence of St. John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000;15:61-8. |
| 4899 | Linde K, Mulrow CD. St. John's wort for depression. Cochrane Database Syst Rev 2000;(2):CD000448. |
| 5096 | Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John's wort in major depression: A randomized, placebo-controlled trial. JAMA 2001;285:1978-86. |
| 5189 | Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 1994;154:7-14. |
| 5192 | Salmaggi P, Bressa GM, Nicchia G, et al. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother Psychosom 1993;59:34-40. |
| 5193 | Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992;44:257-62. |
| 5195 | Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 1990;147:591-5. |
| 5196 | Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990;81:432-6. |
| 5200 | Bell KM, Plon L, Bunney WE Jr, Potkin SG. S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry 1988;145:1110-4. |
| 5231 | Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38:389-416. |
| 5232 | Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137-52. |
| 5444 | Cowley G, Underwood A. Newsweek. July 5, 1999; pp. 46-50. |
| 5446 | Czap A. Beware the son of SAMe. Altern Med Rev 1999;4:73. |
| 6201 | Brown TM. Acute St. John's wort toxicity. Am J Emerg Med 2000;18:231-2. |
| 6239 | Fava M, Borus JS, Alpert JE, et al. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry 1997;154:426-8. |
| 6243 | Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline (2000). Washington, DC: National Academy Press, 2000. Available at: http://books.nap.edu/books/0309065542/html/. |
| 6400 | Brenner R, Azbel V, Madhusoodanan S, et al. Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study. Clin Ther 2000;22:411-9. |
| 6428 | Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 2000;132:743-56. |
| 6434 | Woelk H. Comparison of St. John's wort and imipramine for treating depression: randomized controlled trial. BMJ 2000;321:536-9. |
| 7067 | FDA. Information paper on L-tryptophan and 5-hydroxy-L-tryptophan. Office of Nutritional Products, Labeling, Dietary Supplements. Center for Food Safety and Applied Nutrition. February 2001. |
| 7113 | Maggioni M, Picotti GB, Bondiolotti GP, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand 1990;81:265-70. |
| 7208 | Gelenberg AJ, Wojcik JD, Falk WE, et al. Tyrosine for depression: a double-blind trial. J Affect Disord 1990;19:125-32. |
| 7603 | Caicoya M. Fish consumption and stroke: a community case-control study in Asturias, Spain. Neuroepidemiology 2002;21:107-14. |
| 7809 | Gorski JC, Hamman MA, Wang Z, et al. The effect of St. John's wort on the efficacy of oral contraceptives (abstract MPI-80). Clin Pharmacol Ther 2001;71:P25. |
| 7810 | Hennessy M, Kelleher D, Spiers JP, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75-82. |
| 7812 | Patel S, Robinson R, Burk M. Hypertensive crisis associated with St. John's Wort. Am J Med 2002;112:507-8. |
| 8051 | Shapiro S. L-tryptophan and eosinophilia-myalgia syndrome. Lancet 1994;344:817-9. |
| 8597 | Mazat L, Lafont S, Berr C, et al. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc Natl Acad Sci U S A 2001;98:8145-50. |
| 8699 | Pedersen HS, Mulvad G, Seidelin KN, et al. N-3 fatty acids as a risk factor for haemorrhagic stroke. Lancet 1999;353:812-3. |
| 8801 | Bender NK, Kraynak MA, Chiquette E, et al. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis 1998;5:257-61. |
| 8936 | Calapai G, Crupi A, Firenzuoli F, et al. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of hypericum perforatum. Pharmacopsychiatry 2001;34:45-9. |
| 9108 | Hardy M, Coulter I, Morton SC, et al. S-Adenosyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. Evidence Report/Technology Assessment Number 64. Agency for Healthcare Research and Quality, US Dept of Health and Human Services; 2002. AHRQ publication 02-E033. Rockville, Md. Available at: http://www.ahrq.gov/clinic/tp/sametp.htm. |
| 9109 | Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-Lmethionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in multicenter studies. Am J Clin Nutr 2002;76:1172S-6S. |
| 9110 | Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside--molecular basis of a pleiotrophic molecule. Am J Clin Nutr 2002;76:1151S-7S. |
| 9113 | Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 2002;76:1158S-61S. |
| 9880 | Schwarz UI, Buschel B, Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol 2003;55:112-3. |
| 9931 | Aquilani R, Iadarola P, Boschi F, et al. Reduced plasma levels of tyrosine, precursor of brain catecholamines, and of essential amino acids in patients with severe traumatic brain injury after rehabilitation. Arch Phys Med Rehabil 2003;84:1258-65. |
| 10084 | Johnson KL, Klarskov K, Benson LM, et al. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. J Rheumatol 1999;26:2714-7. |
| 10289 | Simat TJ, Kleeberg KK, Muller B, Sierts A. Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan. Adv Exp Med Biol 1999;467:469-80. |
| 10370 | Calhoun KE, Pommier RF, Muller P, et al. Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant. Arch Surg 2003;138:879-83. |
| 10395 | Pettegrew JW, Levine J, McClure RJ. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 2000;5:616-32. |
| 10754 | National Institutes of Health Consensus Development Conference Statement. Phenylketonuria: Screening and Management http://odp.od.nih.gov/consensus/cons/113/113_statement.htm (Accessed 15 August 2003). |
| 10830 | Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500-4. |
| 10831 | Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med 2000;343:1942-50. |
| 10832 | Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105. |
| 10833 | Remick RA. Diagnosis and management of depression in primary care: a clinical update and review. CMAJ 2002;167:1253-60. |
| 10834 | Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. Am J Psychiatry 2000;157:1925-32. |
| 10835 | Ruo B, Rumsfeld JS, Hlatky MA, et al. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003;290:215-21. |
| 10841 | Kessler RC, Soukup J, Davis RB, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001;158:289-94. |
| 10842 | Knaudt PR, Connor KM, Weisler RH, et al. Alternative therapy use by psychiatric outpatients. J Nerv Ment Dis 1999;187:692-5. |
| 10843 | Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St. John's wort) in major depressive disorder: a randomized controlled trial. JAMA 2002;287:1807-14. |
| 10845 | Hammerness P, Basch E, Ulbricht C, et al. St. John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003;44:271-82. |
| 10847 | Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002;72:276-87. |
| 10848 | Foster BC, Vandenhoek S, Hana J, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003;10:334-42. |
| 10850 | Benjamin J, Agam G, Levine J, et al. Inositol treatment in psychiatry. Psychopharmacol Bull 1995;31:167-75. |
| 10852 | McLean A, Rubinsztein JS, Robbins TW, Sahakian BJ. The effects of tyrosine depletion in normal healthy volunteers: implications for unipolar depression. Psychopharmacology (Berl) 2004;171:286-97. |
| 10857 | van Praag HM. Management of depression with serotonin precursors. Biol Psychiatry 1981;16:291-310. |
| 10858 | Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. J Clin Psychopharmacol 1987;7:127-37. |
| 10859 | Maes M, Christophe A, Delanghe J, et al. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999;85:275-91. |
| 10860 | Tiemeier H, van Tuijl HR, Hofman A, et al. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am J Clin Nutr 2003;78:40-6. |
| 10866 | Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913-9. |
| 10869 | Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003;160:996-8. |
| 10870 | Rapoport SI, Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry 2002;59:592-6. |
| 10871 | Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:267-71. |
| 10872 | Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002;159:477-9. |
| 10874 | Tollefson GD, Haus E, Garvey MJ, et al. 24 hour urinary dehydroepiandrosterone sulfate in unipolar depression treated with cognitive and/or pharmacotherapy. Ann Clin Psychiatry 1990;2:39-45. |
| 10875 | Legrain S, Berr C, Frenoy N, et al. Dehydroepiandrosterone sulfate in a long-term care aged population. Gerontology 1995;41:343-51. |
| 10876 | Barrett-Connor E, von Muhlen D, Laughlin GA, Kripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc 1999;47:685-91. |
| 10877 | Morrison MF, Katz IR, Parmelee P, et al. Dehydroepiandrosterone sulfate (DHEA-S) and psychiatric and laboratory measures of frailty in a residential care population. Am J Geriatr Psychiatry 1998;6:277-84. |
| 10879 | Bottiglieri T, Laundy M, Crellin R, et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000;69:228-32. |
| 10880 | Alpert M, Silva RR, Pouget ER. Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharmacol 2003;23:309-13. |
| 10881 | Tiemeier H, van Tuijl HR, Hofman A, et al. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002;159:2099-101. |
| 10882 | Morris MS, Fava M, Jacques PF, et al. Depression and folate status in the US Population. Psychother Psychosom 2003;72:80-7. |
| 10883 | Tolmunen T, Voutilainen S, Hintikka J, et al. Dietary folate and depressive symptoms are associated in middle-aged Finnish men. J Nutr 2003;133:3233-6. |
| 10884 | Taylor MJ, Carney S, Geddes J, Goodwin G. Folate for depressive disorders. Cochrane Database Syst Rev 2003;(2):CD003390. |
| 10885 | Coppen A, Swade C, Jones SA, et al. Depression and tetrahydrobiopterin: the folate connection. J Affect Disord 1989;16:103-7. |
| 10886 | Passeri M, Cucinotta D, Abate G, et al. Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. Aging (Milano) 1993;5:63-71. |
| 10887 | Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990;336:392-5. |
| 10888 | Bell IR, Edman JS, Morrow FD, et al. Brief communication. Vitamin B1, B2, and B6 augmentation of tricyclic antidepressant treatment in geriatric depression with cognitive dysfunction. J Am Coll Nutr 1992;11:159-63. |
| 10889 | Oren DA, Teicher MH, Schwartz PJ, et al. A controlled trial of cyanocobalamin (vitamin B12) in the treatment of winter seasonal affective disorder. J Affect Disord 1994;32:197-200. |
| 10892 | Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-66. |
| 10893 | Kang BJ, Lee SJ, Kim MD, Cho MJ. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol 2002;17:279-84. |
| 10894 | Nurnberg HG, Hensley PL, Gelenberg AJ, et al. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA 2003;289:56-64. |
| 11154 | Shelton RC. St John's Wort for the treatment of depression. Lancet Neurol 2002;1:275. |